112 related articles for article (PubMed ID: 2675195)
1. Hyperlocomotion induced by dopamine or cholecystokinin + dopamine in the nucleus accumbens is not modified by chronic lithium treatment.
Zohar J; Murphy DL; Crawley JN
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(5):775-9. PubMed ID: 2675195
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
Crawley JN; Stivers JA; Blumstein LK; Paul SM
J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
[TBL] [Abstract][Full Text] [Related]
3. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
Crawley JN; Hommer DW; Skirboll LR
Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin potentiation of dopamine-mediated behaviors in the nucleus accumbens.
Crawley JN
Ann N Y Acad Sci; 1985; 448():283-92. PubMed ID: 3861122
[No Abstract] [Full Text] [Related]
5. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.
Crawley JN
Brain Res; 1988 Nov; 473(2):398-400. PubMed ID: 3233498
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
[TBL] [Abstract][Full Text] [Related]
7. Enhanced dopamine receptor activation in accumbens and frontal cortex has opposite effects on medial forebrain bundle self-stimulation.
Olds ME
Neuroscience; 1990; 35(2):313-25. PubMed ID: 2199840
[TBL] [Abstract][Full Text] [Related]
8. Involvement of D2 dopamine receptors in the opposing effects of two CCK-B agonists in a spatial recognition memory task: role of the anterior nucleus accumbens.
Léna I; Dh tel H; Garbay C; Daugé V
Psychopharmacology (Berl); 2001 Jan; 153(2):170-9. PubMed ID: 11205416
[TBL] [Abstract][Full Text] [Related]
9. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
Crawley JH
Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
[TBL] [Abstract][Full Text] [Related]
10. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
Wang RY; Hu XT
Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens.
Yim CC; Mogenson GJ
Brain Res; 1991 Feb; 541(1):12-20. PubMed ID: 2029612
[TBL] [Abstract][Full Text] [Related]
12. The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat.
Daugé V; Dor A; Féger J; Roques BP
Eur J Pharmacol; 1989 Apr; 163(1):25-32. PubMed ID: 2744093
[TBL] [Abstract][Full Text] [Related]
13. The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.
Hamilton M; Sheehan MJ; De Belleroche J; Herberg LJ
Neurosci Lett; 1984 Jan; 44(1):77-82. PubMed ID: 6717857
[TBL] [Abstract][Full Text] [Related]
14. Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of rat forebrain.
Campbell A; Villavicencio AT; Yeghiayan SK; Balikian R; Baldessarini RJ
Brain Res; 1997 Oct; 771(1):55-62. PubMed ID: 9383008
[TBL] [Abstract][Full Text] [Related]
15. Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action.
Costall B; Domeney AM; Naylor RJ
Psychopharmacology (Berl); 1984; 82(3):174-80. PubMed ID: 6144126
[TBL] [Abstract][Full Text] [Related]
16. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
Costall B; Domeney AM; Naylor RJ; Tyers MB
Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
[TBL] [Abstract][Full Text] [Related]
17. Influence of cholecystokinin on central monoaminergic pathways.
Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
[TBL] [Abstract][Full Text] [Related]
18. Effect of injection of CCK-8 into the nucleus caudatus on the behavior of rats.
Takeda Y; Kamiya Y; Honda K; Takano Y; Kamiya H
Jpn J Pharmacol; 1986 Apr; 40(4):569-75. PubMed ID: 3735805
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor elevation by cholecystokinin.
Dumbrille-Ross A; Seeman P
Peptides; 1984; 5(6):1207-12. PubMed ID: 6531273
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.
Marshall FH; Barnes S; Hughes J; Woodruff GN; Hunter JC
J Neurochem; 1991 Mar; 56(3):917-22. PubMed ID: 1993898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
